Your browser doesn't support javascript.
loading
Inherited variants affecting RNA editing may contribute to ovarian cancer susceptibility: results from a large-scale collaboration.
Permuth, Jennifer B; Reid, Brett; Earp, Madalene; Chen, Y Ann; Monteiro, Alvaro N A; Chen, Zhihua; Chenevix-Trench, Georgia; Fasching, Peter A; Beckmann, Matthias W; Lambrechts, Diether; Vanderstichele, Adriaan; Van Niewenhuyse, Els; Vergote, Ignace; Rossing, Mary Anne; Doherty, Jennifer Anne; Chang-Claude, Jenny; Moysich, Kirsten; Odunsi, Kunle; Goodman, Marc T; Shvetsov, Yurii B; Wilkens, Lynne R; Thompson, Pamela J; Dörk, Thilo; Bogdanova, Natalia; Butzow, Ralf; Nevanlinna, Heli; Pelttari, Liisa; Leminen, Arto; Modugno, Francesmary; Edwards, Robert P; Ness, Roberta B; Kelley, Joseph; Heitz, Florian; Karlan, Beth; Lester, Jenny; Kjaer, Susanne K; Jensen, Allan; Giles, Graham; Hildebrandt, Michelle; Liang, Dong; Lu, Karen H; Wu, Xifeng; Levine, Douglas A; Bisogna, Maria; Berchuck, Andrew; Cramer, Daniel W; Terry, Kathryn L; Tworoger, Shelley S; Poole, Elizabeth M; Bandera, Elisa V.
Affiliation
  • Permuth JB; Department of Cancer Epidemiology, Moffitt Cancer Center, Tampa, FL, USA.
  • Reid B; Department of Cancer Epidemiology, Moffitt Cancer Center, Tampa, FL, USA.
  • Earp M; Department of Health Science Research, Division of Epidemiology, Mayo Clinic, Rochester, MN, USA.
  • Chen YA; Department of Biostatistics and Bioinformatics, Moffitt Cancer Center, Tampa, FL, USA.
  • Monteiro AN; Department of Cancer Epidemiology, Moffitt Cancer Center, Tampa, FL, USA.
  • Chen Z; Department of Biostatistics and Bioinformatics, Moffitt Cancer Center, Tampa, FL, USA.
  • Chenevix-Trench G; Cancer Genetics Laboratory, Research Division, Peter MacCallum Cancer Centre, Melbourne, Australia.
  • Fasching PA; Genetics and Computational Biology Department, QIMR Berghofer Medical Research Institute, Queensland, Australia.
  • Beckmann MW; David Geffen School of Medicine, Department of Medicine, Division of Hematology and Oncology, University of California at Los Angeles, Los Angeles, CA, USA.
  • Lambrechts D; University Hospital Erlangen, Department of Gynecology and Obstetrics, Friedrich-Alexander-University Erlangen-Nuremberg, Comprehensive Cancer Center, Erlangen, Germany.
  • Vanderstichele A; University Hospital Erlangen, Department of Gynecology and Obstetrics, Friedrich-Alexander-University Erlangen-Nuremberg, Comprehensive Cancer Center, Erlangen, Germany.
  • Van Niewenhuyse E; Vesalius Research Center, VIB, Leuven, Belgium.
  • Vergote I; Laboratory for Translational Genetics, Department of Oncology, University of Leuven, Leuven, Belgium.
  • Rossing MA; Division of Gynecologic Oncology, Department of Obstetrics and Gynaecology and Leuven Cancer Institute, University Hospitals Leuven, Leuven, Belgium.
  • Doherty JA; Division of Gynecologic Oncology, Department of Obstetrics and Gynaecology and Leuven Cancer Institute, University Hospitals Leuven, Leuven, Belgium.
  • Chang-Claude J; Division of Gynecologic Oncology, Department of Obstetrics and Gynaecology and Leuven Cancer Institute, University Hospitals Leuven, Leuven, Belgium.
  • Moysich K; Program in Epidemiology, Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
  • Odunsi K; Department of Epidemiology, University of Washington, Seattle, WA, USA.
  • Goodman MT; Department of Epidemiology, Geisel School of Medicine, Dartmouth College, Hanover, NY, USA.
  • Shvetsov YB; German Cancer Research Center, Division of Cancer Epidemiology, Heidelberg, Germany.
  • Wilkens LR; University Cancer Center Hamburg (UCCH), University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
  • Thompson PJ; Department of Cancer Prevention and Control, Roswell Park Cancer Institute, Buffalo, NY, USA.
  • Dörk T; Department of Gynecologic Oncology, Roswell Park Cancer Institute, Buffalo, NY, USA.
  • Bogdanova N; Cancer Prevention and Control, Samuel Oshin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
  • Butzow R; Community and Population Health Research Institute, Department of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
  • Nevanlinna H; Cancer Epidemiology Program, University of Hawaii Cancer Center, Honolulu, HI, USA.
  • Pelttari L; Cancer Epidemiology Program, University of Hawaii Cancer Center, Honolulu, HI, USA.
  • Leminen A; Cancer Prevention and Control, Samuel Oshin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
  • Modugno F; Community and Population Health Research Institute, Department of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
  • Edwards RP; Gynaecology Research Unit, Hannover Medical School, Hannover, Germany.
  • Ness RB; Radiaton Oncology Research Unit, Hannover Medical School, Hannover, Germany.
  • Kelley J; Department of Pathology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
  • Heitz F; Department of Obstetrics and Gynecology, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland.
  • Karlan B; Department of Obstetrics and Gynecology, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland.
  • Lester J; Department of Obstetrics and Gynecology, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland.
  • Kjaer SK; Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
  • Jensen A; Ovarian Cancer Center of Excellence, Womens Cancer Research Program, Magee-Womens Research Institute & University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA.
  • Giles G; Department of Epidemiology, University of Pittsburgh Graduate School of Public Health, Pittsburgh, PA, USA.
  • Hildebrandt M; Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
  • Liang D; Ovarian Cancer Center of Excellence, Womens Cancer Research Program, Magee-Womens Research Institute & University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA.
  • Lu KH; The University of Texas School of Public Health, Houston, TX, USA.
  • Wu X; Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
  • Levine DA; Department of Gynecology and Gynecologic Oncology, Kliniken Essen-Mitte/Evang. Huyssens-Stiftung/Knappschaft GmbH, Essen, Germany.
  • Bisogna M; Department of Gynecology and Gynecologic Oncology, Dr. Horst Schmidt Klinik Wiesbaden, Wiesbaden, Germany.
  • Berchuck A; Women's Cancer Program at the Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, California, USA.
  • Cramer DW; Women's Cancer Program at the Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, California, USA.
  • Terry KL; Department of Virus, Lifestyle and Genes, Danish Cancer Society Research Center, Copenhagen, Denmark.
  • Tworoger SS; Department of Gynaecology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
  • Poole EM; Department of Virus, Lifestyle and Genes, Danish Cancer Society Research Center, Copenhagen, Denmark.
  • Bandera EV; Cancer Epidemiology Centre, Melbourne, Australia.
Oncotarget ; 7(45): 72381-72394, 2016 11 08.
Article in En | MEDLINE | ID: mdl-27911851
RNA editing in mammals is a form of post-transcriptional modification in which adenosine is converted to inosine by the adenosine deaminases acting on RNA (ADAR) family of enzymes. Based on evidence of altered ADAR expression in epithelial ovarian cancers (EOC), we hypothesized that single nucleotide polymorphisms (SNPs) in ADAR genes modify EOC susceptibility, potentially by altering ovarian tissue gene expression. Using directly genotyped and imputed data from 10,891 invasive EOC cases and 21,693 controls, we evaluated the associations of 5,303 SNPs in ADAD1, ADAR, ADAR2, ADAR3, and SND1. Unconditional logistic regression was used to estimate odds ratios (OR) and 95% confidence intervals (CI), with adjustment for European ancestry. We conducted gene-level analyses using the Admixture Maximum Likelihood (AML) test and the Sequence-Kernel Association test for common and rare variants (SKAT-CR). Association analysis revealed top risk-associated SNP rs77027562 (OR (95% CI)= 1.39 (1.17-1.64), P=1.0x10-4) in ADAR3 and rs185455523 in SND1 (OR (95% CI)= 0.68 (0.56-0.83), P=2.0x10-4). When restricting to serous histology (n=6,500), the magnitude of association strengthened for rs185455523 (OR=0.60, P=1.0x10-4). Gene-level analyses revealed that variation in ADAR was associated (P<0.05) with EOC susceptibility, with PAML=0.022 and PSKAT-CR=0.020. Expression quantitative trait locus analysis in EOC tissue revealed significant associations (P<0.05) with ADAR expression for several SNPs in ADAR, including rs1127313 (G/A), a SNP in the 3' untranslated region. In summary, germline variation involving RNA editing genes may influence EOC susceptibility, warranting further investigation of inherited and acquired alterations affecting RNA editing.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Ovarian Neoplasms / Genetic Variation / RNA Editing Limits: Animals / Female / Humans / Middle aged Language: En Journal: Oncotarget Year: 2016 Document type: Article Affiliation country: United States Country of publication: United States

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Ovarian Neoplasms / Genetic Variation / RNA Editing Limits: Animals / Female / Humans / Middle aged Language: En Journal: Oncotarget Year: 2016 Document type: Article Affiliation country: United States Country of publication: United States